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Introduction
Lower respiratory tract infections (LRTIs) are responsible for 28% of 
preventable and treatable child deaths under 2 years in the world (1). 
The most common causes of LTRIs below 2 years are viruses (2). Recent 
advances in respiratory tract infections have led to isolation of new 
agents such as human metapneumovirus (hMPV), coronaviruses, human 
bocavirus, parvovirus type 4 and type 5, and polyomavirus in addition 
to classical respiratory tract viruses such as influenza, parainfluenza, 
adenovirus and respiratory syncytial virus (RSV) (3). HMPV was first isolated 
from the airways in the Netherlands in 2001 as a new paramyxovirus (4). 
HMPV causes LRTIs such as bronchiolitis and pneumonia besides upper 
respiratory tract infection.
In this article, a 23-month-old patient, who was followed-up with 
recurrent wheezing, respiratory distress, hypoxemia and in whom hMPV 
was identified as the etiologic agent, was presented for the purpose of 
drawing attention to the recent identification of the agent and its rare 
occurrence in the clinical practice.
Case Report
A 23-month-old boy was admitted to the hospital due to respiratory 
distress. He had a history of recurrent wheezing for a year and severe 
wheezing episodes, and he was hospitalized 3 times. He was on 
nebulized salbutamol, budesonide and montelukast therapy. The 
patient’s respiratory distress had persisted for the last two weeks despite 
treatment. His vital signs were as follows: body temperature: 36.7 ºC, 
ÖZABSTRACT
Dünyada 2 yaş altı önlenebilir ve tedavi edilebilir çocuk 
ölümlerinin %28’inden alt solunum yolu enfeksiyonları 
sorumludur. Son yıllarda solunum yolu enfeksiyonlarının 
etmenlerine yönelik yapılan çalışmalardaki gelişmelere 
bağlı olarak klasik solunum yolu virüslerinin yanında insan 
metapnömovirüs (iMPV), koronavirüsler, insan bocavirüs, 
parvovirüs tip 4 ve tip 5 ve poliyomavirüs gibi yeni etmenler de 
tespit edilmiştir. iMPV ilk kez 2001 yılında Hollanda’da tespit 
edilmiştir. iMPV hafif üst solunum yolu enfeksiyonundan, 
bronşiolit ve astım atağına, ciddi pnömoniden akut 
respiratuvar distress sendromuna kadar varan klinik tablolara 
yol açabilir. Bu makalede tekrarlayan hışıltı atağı, solunum 
sıkıntısı ve oksijen ihtiyacı nedeniyle takip edilen ve etken 
olarak iMPV saptanan 23 aylık hasta, etkenin son yıllarda 
yeni tanımlanması ve klinikte nadir görülüp tespit edilmesine 
dikkat çekmek amacıyla sunulmuştur.
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Lower respiratory tract infections are responsible for 28% of 
preventable and treatable childhood deaths under 2 years 
of age in the world. In recent years, due to advances on the 
factors of respiratory tract infections, new agents such as 
human metapneumovirus (hMPV), coronaviruses, human 
bocavirus, parvovirus type 4 and type 5, and polyomavirus 
have been identified in addition to classical respiratory tract 
viruses. hMPV was first identified in the Netherlands in 2001. 
hMPV can lead to clinical manifestations ranging from mild 
upper respiratory tract infection, bronchiolitis and asthma 
attack, severe pneumonia to acute respiratory distress 
syndrome. In this article, a 23-month-old patient, who was 
followed-up with recurrent wheezing, respiratory distress, 
hypoxemia and in whom hMPV was identified as an etiologic 
agent, was presented for the purpose of drawing attention to 
the recent identification of the agent and its rare occurrence in 
the clinical practice.
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respiratory rate: 50/minute (min), oxygen saturation (sPO
2
): 96%, and 
pulse: 136/min. Physical examination revealed diffuse rhonchi in both 
lungs, and basal crepitant crackles. Laboratory results were as follows: 
white blood cells: 19.000/mm3 (range: 4.000-10.200/mm3), neutrophil 
count: 9.760/mm3, Hemoglobin: 13.1g/dL (range: 12-18 g/dL), platelet 
count: 405.000/mm3 (range: 142.000-424.000/mm3), C-reaktif protein 
(CRP): 54.4 mg/dL (range: 0-5 mg/dL), sedimentation: 16/hr. (normal: 
<20). There was left perihilar fullness in the chest X-ray (Figure 1). The 
patient was started on salbutamol and ipratropium bromide treatment 
due to respiratory distress, and cefuroxime axetil treatment with a 
pre-diagnosis of bronchopneumonia with suspected bacterial agent. 
After the third day of treatment, systemic steroid (1 mg/kg/day) was 
initiated due to ongoing rhonchi. In order to investigate the etiology 
of recurrent wheezing episodes, immunoglobulin (Ig) G, A, M, E, IgG 
subgroups, specific antibody responses to past infections (anti-CMV 
IgG, anti-Rubella IgG and anti-HBs), CD3 in flow cytometric evaluation 
(T-cell), CD4, CD8, CD19 (B-cell), CD16 and CD56 (NK-cell) lymphocyte 
subgroups, isohemagglutinin (anti-A and anti-B) tests were performed 
and results were evaluated as normal. Purified protein derivative test 
(2 times) was negative. The sweat test was in normal range with 5.6 
(range: 0-60) mmol/L. On the 10th day of the follow-up, his antibiotic 
treatment was discontinued and the dose of nebulized salbutamol and 
ipratropium bromide was reduced. On the 11th day of admission, his 
clinical condition improved and he complained of recurrent fever and 
vomiting while trying to cease the bronchodilator treatment. Urine and 
stool examination (adenovirus, rotavirus and microscopic examination) 
were evaluated as normal. At follow-up, complaints of 39 ºC fever, 
wheezing and respiratory distress, tachypnea and hypoxemia occurred, 
and the sPO
2
 of the patient decreased to 88%. Supportive oxygen therapy 
was initiated. Blood cultures were obtained and a respiratory viral panel 
examination with polymerase chain reaction (PCR) was performed from 
the nasopharynx swab (Rotor-Gene Q platform,Qiagen, Germany). A total 
of 20 viruses were screened from 10 virus groups (influenza, rhinovirus, 
coronavirus, parainfluenza, hMPV A/B, bocavirus, RSV, adenovirus, 
enterovirus, and parechovirus). Despite negative blood cultures, hMPV 
was isolated from nasopharyngeal swab using PCR method. The patient 
was diagnosed as having hMPV-induced LRTI (bronchiolitis attack) and 
was discharged following observed improvement in hypoxemia and 
chest X-ray with conservative treatment (Figure 2). Oral patient consent 
was obtained from the family.
Discussion 
HMPV is an RNA virus from the paramyxovirus family. People are the 
only source of infection for the virus. The disease is transmitted through 
the respiratory tract secretions of infected persons by droplets or direct 
contact (5). Personal hygiene and contact precautions are the main 
preventive methods for the prevention of virus transmission (6). Its 
frequency increases in winter and spring months. The most frequent 
months are March and April (7). The incidence is higher in boys than 
in girls. Unlike the RSV, it is more common in children between 6-21 
months. Prodrome period lasts for 5-6 days and the clinical symptoms 
occur after (8). The typical course is the LRTI findings starting after a 
short asymptomatic period following the symptoms of the upper 
respiratory tract that lasts for two days. In many patients, wheezing 
lasts for several days, however, as in our patient, it may lead to LRTI 
(bronchiolitis) after an asymptomatic period, and may cause recurrent 
wheezing, and wheezing attacks and cough may continue for weeks in 
individuals with similar diseases (9,10).
The most common clinical findings are cough, runny nose, fever, 
restlessness, anorexia, wheezing and rarely nausea, vomiting and 
diarrhea. Auscultation findings include wheezing (52%), and less 
frequently rhonchi (20%) and crackles (8%) (11). Radiographically, 
chest X-ray can show consolidation, perihilar infiltration, atelectasis 
and hyperinflation (12). Lymphopenia, transaminase elevation and 
CRP elevation can be detected in the laboratory tests (13). HMPV can 
lead to clinical manifestations ranging from mild upper respiratory 
tract infection, bronchiolitis and asthma attack, severe pneumonia to 
acute respiratory distress syndrome (9). The most common reason for 
hospitalization in hMPV infection is bronchiolitis and pneumonia (14).
In a study by Williams et al. (11), 59% of the patients hospitalized for LRTI 
and diagnosed as having hMPV were evaluated as bronchiolitis, 8% as 
pneumonia, 18% as croup and 14% as asthma attack. Xepapadaki et al. 
(14) found hMPV in 16% of the patients hospitalized for bronchiolitis. In 
our patient, the clinical findings started as recurrent wheezing, followed 
Figure 1. Left perihilar fullness, infiltrative appearance in the right 
lower and middle zones suggesting pneumonia and bilateral significant 
hyperaeration are noteworthy
Figure 2. Prominent bronchovascular structures
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by nasal discharge, subfebrile fever, nausea, vomiting and diarrhea, 
followed by a fever of 39 ºC, respiratory distress and recurrent wheezing. 
There were no significant laboratory findings in our patient’s blood tests 
except increased CRP (54.4 mg/dL). There was a perihilar infiltration in 
the chest X-ray.
Although the gold standard method is cell culture, the PCR test is widely 
used in diagnosis. It is not clinically useful since reproduction in viral 
cell culture can last 10-14 days (12). There was no growth in blood, urine 
and throat cultures of our patient. The hMPV was found to be positive by 
real-time PCR method in screening with viral respiratory panel.
There is no antiviral drug or vaccine approved for the treatment 
and prophylaxis of hMPV infection. Oxygen support therapy, and 
intravenous fluid therapy in patients with reduced oral intake, vomiting 
and diarrhea are supportive treatments. Bronchodilator and steroid 
therapy may be used in cases of asthma exacerbation. Antibiotic therapy 
may be necessary in cases of bacterial superinfection. There are studies 
suggesting that ribavirin and intravenous Ig treatment inhibit hMPV 
infection in vitro. There are case reports of ribavirin and intravenous 
Ig treatment used in the treatment of immunosuppressive patients 
(12,15). The patient was given antibiotherapy due to the initial diagnosis 
of bacterial pneumonia, and conservative treatment was continued 
despite clinical deterioration after the diagnosis of hMPV-induced LRTI 
(bronchiolitis). The patient was discharged with healing after intravenous 
hydration, mask oxygen therapy and nebulized salbutamol.
Our patient was probably infected with hMPV infection while he 
was inpatient for correction of respiratory distress due to recurrent 
wheezing, but he was undergoing the prodrome period of the disease. 
In the first week of hospitalization for wheezing, the infection presented 
with upper respiratory tract symptoms in the asymptomatic period and 
became symptomatic with subsequent LRTI findings. In our patient, it is 
important to detect recurrent wheezing attack and to reveal the clinical 
picture that is caused by hMPV. Again, according to the literature, it is 
significant to show that the supportive treatment will be sufficient and 
the clinic is improved in the patient.
Conclusion
In cases of recurrent wheezing and asthma bronchitis exacerbations, 
hMPV infection should be considered and the clinical picture that it may 
cause should be known by other physicians, such as allergy and chest 
diseases specialists, dealing with respiratory diseases.
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